Codes and Frequencies
Description
STIMIMPOT (V785L) indicates whether the woman reported "impotence" as a possible symptom of STI (sexually transmitted infection) in men.
Comparability — Index
GENERAL Bangladesh |
Jordan |
Kenya |
Comparability
Along with universe differences, STIMIMPOT (V785L) has some variation in question wording that broadly applies to the "symptoms of STI" series. For discussion of question wording in this variable series, see the comparability section of STIMDK (V785Z).
Women who had not heard of sexually transmitted infections apart from AIDS were not asked about STI symptoms, and they were automatically coded "No" in this series, unless otherwise noted in the comparability text below. For the variable indicating whether the woman has heard of STIs other than AIDS, see STIHEARDOTH (V785).
Comparability - Standard DHS
STIMIMPOT (V785L) appears in phase IV of the Standard DHS questionnaire but is not included in subsequent phases of the standard questionnaire.
Comparability — Bangladesh [top]
Unlike the majority of samples, the 2000 Bangladesh sample does not include women who had not heard of STIs other than AIDS in the universe for the "symptoms of STI" variable series. These women are coded as "not in universe" instead of in the "No" category.
The 2004 Bangladesh sample does not have the same comparability issue as Bangladesh 2000; the earlier sample follows the coding conventions of most samples that have the "symptoms of STI" questions.
Comparability — Jordan [top]
Unlike the majority of samples, the 2007 Jordan sample does not include women who had not heard of STIs other than AIDS in the universe for the "symptoms of STI" variable series. These women are coded as "not in universe" instead of in the "No" category.
The 2002 Jordan sample does not have the same comparability issue as Jordan 2007; the earlier sample follows the coding conventions of most samples that have the "symptoms of STI" questions.
Comparability — Kenya [top]
Unlike the majority of samples, the Kenya 2008 sample does not include women who had not heard of STIs other than AIDS in the universe for the "symptoms of STI" variable series. These women are coded as "not in universe" instead of in the "No" category.
The Kenya 2003 sample does not have the same comparability issue as Kenya 2008; the earlier sample follows the coding conventions of most samples that have the "symptoms of STI" questions.
Universe
- Bangladesh 2000: Ever-married women age 10-49 who have heard about sexually transmitted infections apart from AIDS.
- Bangladesh 2004: Ever-married women age 10-49.
- Benin 2001: All women age 15-49.
- Benin 2006: All women age 15-49.
- Burkina Faso 2003: All women age 15-49.
- Cameroon 2004: All women age 15-49.
- Chad 2004: All women age 15-49.
- Congo (Democratic Republic) 2007: All women age 15-49.
- Congo Brazzaville 2005: Women age 15-49 who have heard about sexually transmitted infections apart from AIDS.
- Eswatini (Swaziland) 2006: All women age 15-49.
- Ethiopia 2000: All women age 15-49.
- Gabon 2000: Women age 15-49 who have heard about sexually transmitted infections apart from AIDS.
- Ghana 2003: All women age 15-49.
- Jordan 2002: Ever-married women age 15-49.
- Jordan 2007: Ever-married women age 15-49 who have heard about sexually transmitted infections apart from AIDS.
- Kenya 2003: All women age 15-49.
- Kenya 2008: Women age 15-49 who have heard about sexually transmitted infections apart from AIDS.
- Lesotho 2004: All women age 15-49.
- Madagascar 2003: All women age 15-49.
- Madagascar 2008: All women age 15-49.
- Malawi 2004: All women age 15-49.
- Mali 2001: All women age 15-49.
- Mali 2006: All women age 15-49.
- Morocco 2003: All women age 15-49.
- Mozambique 2003: All women age 15-49.
- Niger 2006: All women age 15-49.
- Nigeria 2003: All women age 15-49.
- Rwanda 2000: All women age 15-49.
- Rwanda 2005: All women age 15-49.
- Senegal 2005: All women age 15-49.
- Tanzania 2004: All women age 15-49.
- Uganda 2001: All women age 15-49.
- Zambia 2001: All women age 15-49.
- Zimbabwe 1999: All women age 15-49.